IL1B and macrophage activation syndrome: The percentage of patients developing MAS in the ESTIS cohort in the first two years (18%) aligns with historically reported rates, suggesting that early initiation of IL‐1–targeted monotherapy for sJIA‐SD does not reduce MAS incidence in the first two years of disease.17, 20, 27, 31, 32